Whitespace Analysis

Find crowded markets, emerging opportunities, and underserved indications by trial activity and sponsor concentration.

Limited-time launch pricing

$99/month · $990/year

Save $198 - 2 months free - with yearly

Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.

Competitive Density Analysis

Data updated: May 20, 2026

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication	TA	Active Trials	Phase 3	Phase 2	Sponsors
Solid Tumor (Advanced)	Oncology	3462	375	1801	759
Non-Hodgkin Lymphoma	Oncology	1604	179	1031	227
Breast Cancer	Oncology	1502	323	896	193
NSCLC	Oncology	1432	279	888	316
Colorectal Cancer	Oncology	1122	185	737	221
Prostate Cancer	Oncology	866	156	542	146
AML	Oncology	686	76	383	111
Multiple Myeloma	Oncology	666	113	395	88
Pancreatic Cancer	Oncology	641	70	410	191
Hepatocellular Carcinoma	Oncology	623	93	392	119
Lung Cancer (General)	Oncology	559	75	347	105
Hematologic Malignancies	Oncology	552	61	332	83
Ovarian Cancer	Oncology	540	82	300	159
Melanoma	Oncology	519	61	312	141
Head and Neck Cancer	Oncology	519	55	332	147

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication	TA	Phase 3	% of Trials	Active	Sponsors
Solid Tumor (Advanced)	Oncology	375	11%	3462	759
Breast Cancer	Oncology	323	22%	1502	193
NSCLC	Oncology	279	19%	1432	316
Colorectal Cancer	Oncology	185	16%	1122	221
Non-Hodgkin Lymphoma	Oncology	179	11%	1604	227
Prostate Cancer	Oncology	156	18%	866	146
Stroke	Cardiovascular	155	43%	359	54
Obesity	Metabolic	135	26%	510	92
Multiple Myeloma	Oncology	113	17%	666	88
Acute Pain	Pain	97	25%	391	40
Hepatocellular Carcinoma	Oncology	93	15%	623	119
Hypertension	Cardiovascular	88	29%	307	82

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication	TA	Trials/Sponsor	Active	Sponsors
Chronic Pain	Pain	20	60	3
HIV	Infectious Disease	17.8	303	17
Sepsis	Infectious Disease	14.5	116	8
Postoperative Pain	Pain	13.1	170	13
Atrial Fibrillation	Cardiovascular	13	117	9
Opioid Use Disorder	CNS	12.9	129	10
ADHD	CNS	12.7	38	3
Alcohol Use Disorder	CNS	12.4	112	9
Nausea/Vomiting	Gastrointestinal	12	48	4
PTSD	CNS	11.4	80	7

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication	TA	Sponsors	Active	Phase 3
Solid Tumor (Advanced)	Oncology	759	3462	375
NSCLC	Oncology	316	1432	279
Non-Hodgkin Lymphoma	Oncology	227	1604	179
Colorectal Cancer	Oncology	221	1122	185
Breast Cancer	Oncology	193	1502	323
Pancreatic Cancer	Oncology	191	641	70
Ovarian Cancer	Oncology	159	540	82
Head and Neck Cancer	Oncology	147	519	55
Prostate Cancer	Oncology	146	866	156
Melanoma	Oncology	141	519	61

Showing top indications in each category

Upgrade to Pro for full competitive density analysis across 143 indications

See Pro Features

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2008+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.